Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP2 | P08253 | 1/20 | 0.40 |
| ▸ | MMP9 | P14780 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | INMT | O95050 | 1/20 | 0.33 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.31 |
| ▸ | ACE | P12821 | 2/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3077849 | 0.78 | MMP2 (0.36) | MMP2MMP9HTT | |
| SCHEMBL3085766 | 0.76 | MMP2 (0.35) | MMP2MMP9KMT2APOLB | |
| SCHEMBL23505952 | 0.75 | — | — | |
| SCHEMBL9207189 | 0.75 | MMP2 (0.37) | MMP2MMP9KMT2AHTTALDH1A1 | |
| SCHEMBL21424968 | 0.71 | ITGB1 (0.39) | KMT2AL3MBTL1POLBP2RX7ACE | |
| SCHEMBL1587390 | 0.68 | P2RX7 (0.51) | KMT2AP2RX7ACE | |
| SCHEMBL1914212 | 0.68 | P2RX7 (0.51) | KMT2AP2RX7ACE | |
| SCHEMBL1636787 | 0.68 | P2RX7 (0.46) | KMT2AL3MBTL1P2RX7ACETDP1 | |
| SCHEMBL1651090 | 0.68 | P2RX7 (0.51) | KMT2AP2RX7ACE | |
| SCHEMBL3336304 | 0.67 | P2RX7 (0.45) | KMT2AL3MBTL1ALDH1A1HPGDP2RX7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160287563-A1 | Cysteine Prodrugs | PROMENTIS PHARMACEUTICALS, INC. (US) | 2016-10-06 | — | — | US | disclosed |
| US-20160287563-A1 | Cysteine Prodrugs | PROMENTIS PHARMACEUTICALS, INC. (US) | 2016-10-06 | — | — | US | disclosed |
| US-20160287563-A1 | Cysteine Prodrugs | PROMENTIS PHARMACEUTICALS, INC. (US) | 2016-10-06 | — | — | US | disclosed |
| US-9457014-B2 | Cysteine prodrugs | PROMENTIS PHARMACEUTICALS, INC. (US) | 2016-10-04 | — | — | US | disclosed |
| US-9457014-B2 | Cysteine prodrugs | PROMENTIS PHARMACEUTICALS, INC. (US) | 2016-10-04 | — | — | US | disclosed |
| US-9457014-B2 | Cysteine prodrugs | PROMENTIS PHARMACEUTICALS, INC. (US) | 2016-10-04 | — | — | US | disclosed |
| US-20160081987-A1 | Cysteine Prodrugs | PROMENTIS PHARMACEUTICALS, INC. (US) | 2016-03-24 | — | — | US | disclosed |
| US-20160081987-A1 | Cysteine Prodrugs | PROMENTIS PHARMACEUTICALS, INC. (US) | 2016-03-24 | — | — | US | disclosed |
| US-20160081987-A1 | Cysteine Prodrugs | PROMENTIS PHARMACEUTICALS, INC. (US) | 2016-03-24 | — | — | US | disclosed |
| EP-2736890-A1 | CYSTEINE PRODRUGS | Promentis Pharmaceuticals, Inc. (US) | 2014-06-04 | — | — | EP | disclosed |
| WO-2013016727-A1 | CYSTEINE PRODRUGS | PROMENTIS PHARMACEUTICALS, INC. (US) | 2013-01-31 | — | — | WO | disclosed |
| WO-2013016727-A1 | CYSTEINE PRODRUGS | PROMENTIS PHARMACEUTICALS, INC. (US) | 2013-01-31 | — | — | WO | disclosed |
| US-7109223-B2 | Oxazolidin-2-one and thiazolidin-2-one derivatives for use as EP4 receptor agonists in the treatment of glaucoma | MERCK & CO. INC. (US) | 2006-09-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160287563-A1 | Cysteine Prodrugs | SLC7A11, GCLC, CTH | MMP2 2984/4885MMP9 3226/4885KMT2A 2370/4885 |
| US-20160081987-A1 | Cysteine Prodrugs | SLC7A11, GCLC, CTH | MMP2 2984/4885MMP9 3226/4885KMT2A 2370/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.